Loading...
•
Dec 31, 2020
Ampio Q4 2020 Earnings Report
Ampio reported financial results for Q4 2020 and provided a business update.
Key Takeaways
Ampio Pharmaceuticals reported its annual financial results for the year ended December 31, 2020. The company's cash and cash equivalents totaled $17.3 million, and research and development expenditures were $9.2 million.
FDA recommended a randomized, double-blinded, placebo-controlled Phase II trial for IV and Inhaled Ampion.
Proposal submitted to FDA regarding Osteoarthritis of the Knee (OAK) Phase III clinical trial.
Cash and cash equivalents totaled $17.3 million at December 31, 2020.
Research and development expenditures were $9.2 million for the year ended December 31, 2020.
Ampio
Ampio
Forward Guidance
Ampio expects to have sufficient cash to fund operations through the first quarter of 2022.